Hot Investor Mandate: CVC Fund Invests Up to $10M, Actively Seeking Novel Drug Delivery Systems in Oncology, Cardiovascular, Chronic Disease, and Pulmonary Indications

4 Aug

A corporate venture arm of a leading electronic solutions provider focuses on medical and pharmaceutical sectors, among other areas. The firm is actively looking to build and expand their pipeline and will focus on strategic investments in which the firm could bring significant value and those that supplement the firm’s business areas. The firm invests up to $10M over the lifetime of the company, usually between Series A to C rounds but will look at Seed stage within the life science space. The firm usually invests around $1-5M initially and reserves capital for follow-on investment. The firm has a global footprint, with manufacturing plants throughout USA and Asia. The firm is open to global opportunities including those in rapidly growing markets such as China and India.

Within the early-stage life sciences ecosystem, the firm is most interested in novel drug delivery systems with target indications including oncology, cardiovascular, diabetes, and COPD. The firm also looks at technology relating to other chronic illness, consumer health & wellness, and point of care diagnostic systems. The firm also has a strong interest in technologies with a connected health component. The firm is open to all early-stage opportunities that are relevant to the firm’s focus areas, but those who do not yet have a working prototype would be considered too early for the firm. The firm is open to all classes of devices including 510k and PMA. Recently, the firm has invested in a novel inhaled insulin delivery device.

The firm can act as either the lead or co-investor. The firm would prefer to see companies that already have some sort of commercial engagement established. The firm aims to bring strategic value into their portfolio companies, such as working on product design and development. If the company already has such manufacturing partnership established, it is unlikely for the firm to invest in the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: